Biotheus builds on ADC pact with Hansoh; Novartis expands in Singapore; Astellas leaves Cartesian deal

Plus, news about Biocon Biologics, Eris Lifesciences, Aprea Therapeutics and Pi Health:

Biotheus expands ADC deal with Hansoh Pharmaceutical: Under the extended pact, Hansoh will get a license to use an anti-EGFR/cMet bispecific antibody developed by Biotheus to create its own ADC product. Biotheus could receive up to RMB 5 billion ($694 million) in upfront and milestones payments, as well as tiered royalties on net sales. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Study shows radial arterial access superiority in coronary interventions

New data demonstrate the superiority of radial arterial access compared to femoral arterial access for coronary interventions.

May 3, 2024

New hope for stroke patients: University of Cincinnati trial tests unique tongue exercise device

The Gardner Neuroscience Institute, supported by a $660,000 NIH grant, is launching a trial to test an at-home tongue endurance exercise aimed at improving swallowing

January 11, 2024

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

The safety, efficacy, and immunogenicity of a mRNA-based vaccine.

December 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.